Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 6/20 | 0.35 |
| ▸ | ANPEP | P15144 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.33 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739156 | 0.79 | PTGS1 (0.50) | BMP1FOLH1ENPEPANPEPACE | |
| SCHEMBL31514543 | 0.71 | FOLH1 (0.61) | BMP1FOLH1ACENAALAD2RIMKLA | |
| SCHEMBL29774451 | 0.68 | PTGS1 (0.52) | BMP1FOLH1ENPEPANPEPACE | |
| SCHEMBL30824322 | 0.67 | FOLH1 (0.65) | BMP1FOLH1ENPEPANPEPACE | |
| SCHEMBL17884294 | 0.67 | FOLH1 (0.59) | BMP1FOLH1ENPEPANPEPACE | |
| SCHEMBL3395647 | 0.67 | KDM4E (0.69) | FOLH1ACENAALAD2KDM4EMAPT | |
| SCHEMBL3395639 | 0.67 | KDM4E (0.69) | FOLH1ACENAALAD2KDM4EMAPT | |
| SCHEMBL14012326 | 0.66 | FOLH1 (0.46) | BMP1FOLH1ENPEPANPEPACE | |
| SCHEMBL17888187 | 0.66 | NOD1 (0.49) | BMP1FOLH1ENPEPANPEPACE | |
| SCHEMBL9760353 | 0.65 | FOLH1 (0.61) | BMP1FOLH1ENPEPANPEPACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392639-B1 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-6916850-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6900218-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030013847-A1 | Cytoprotective agents | MONSANTO TECHNOLOGY LLC | 2003-01-16 | — | — | US | disclosed |
| US-20030013846-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013657-A1 | Pyruvate derivatives | MONSANTO TECHNOLOGY, LLC. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013847-A1 | Cytoprotective agents | PC, PDK1, PDK2 | BMP1 4702/4885FOLH1 3095/4885ENPEP 1060/4885 |
| US-20030013657-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | BMP1 4330/4885FOLH1 2710/4885ENPEP 1218/4885 |
| US-20030013846-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | BMP1 4330/4885FOLH1 2710/4885ENPEP 1218/4885 |
| US-20030013656-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | BMP1 4330/4885FOLH1 2710/4885ENPEP 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.